Related medicinesGlucagonDasiglucagon

Where it comes from

Made in
Alpha cells of the pancreatic islets
Sent out by
Falling blood glucose, amino acids after a protein meal, adrenaline and exercise; insulin and somatostatin hold it back
Acts on
  • Liver
  • Fat tissue
  • Heart

What it does

  • Makes the liver break down glycogen and make new glucose 1
  • Raises energy expenditure and fat burning 1
  • Rises wrongly in type 2 diabetes, adding to the high glucose

In medicine

  • Glucagon is the rescue injection for severe hypoglycaemia; a nasal powder (2019) and ready-to-use pens of dasiglucagon (2021) followed 2
  • The glucagon stimulation test probes growth hormone and cortisol reserve
  • Given to relax the gut during imaging and endoscopy

Beyond the body’s own use

  • Glucagon receptor activity is built into the dual and triple agonists survodutide, mazdutide and retatrutide: the glucagon part raises energy expenditure, the GLP-1 part curbs appetite. Mazdutide took off 16.7% of body weight against 1.5% on placebo in a 461-person Chinese phase 3 trial 4 and is approved in China for weight management; the others have reported phase 3 results in obesity and are not approved
  • Blocking the receptor instead was tried and largely abandoned: in phase 2 trials in type 2 diabetes, glucagon receptor antagonists lowered glucose but raised liver fat, liver enzymes and LDL cholesterol 3
  • Pumps that give glucagon alongside insulin, the bihormonal closed loop, are in trials in type 1 diabetes and are not approved

Sources

  1. Müller et al., The new biology and pharmacology of glucagon, Physiological Reviews 2017
  2. Dasiglucagon (Zegalogue), FDA application NDA 214231
  3. Kazda et al., The glucagon receptor antagonist LY2409021 in type 2 diabetes, Diabetes Care 2016
  4. Gao et al., Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2), JAMA 2026

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.